Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Return on Capital Employed (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Return on Capital Employed for 15 consecutive years, with 3.82% as the latest value for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 211.0% year-over-year to 3.82%; the TTM value through Dec 2025 reached 3.82%, down 211.0%, while the annual FY2025 figure was 3.17%, 199.0% down from the prior year.
  • Return on Capital Employed hit 3.82% in Q4 2025 for Sangamo Therapeutics, down from 2.54% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.17% in Q1 2021 and bottomed at 3.82% in Q4 2025.
  • Average Return on Capital Employed over 5 years is 1.35%, with a median of 0.92% recorded in 2023.
  • Year-over-year, Return on Capital Employed tumbled -292bps in 2024 and then skyrocketed 215bps in 2025.
  • Sangamo Therapeutics' Return on Capital Employed stood at 0.3% in 2021, then plummeted by -46bps to 0.43% in 2022, then crashed by -339bps to 1.89% in 2023, then increased by 9bps to 1.71% in 2024, then tumbled by -123bps to 3.82% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 3.82%, 2.54%, and 1.42% for Q4 2025, Q3 2025, and Q2 2025 respectively.